It is “critical” that the government resists any US proposals to “change patent or exclusivity provisions” that could delay the entry of generic and biosimilar medicines to the UK market, the director general of the British Generic Manufacturers Association (BGMA) said in a statement last week (February 6).
Resisting any such change would “deliver on the Conservative party election manifesto”, Mr Smith said in response to a speech made by the secretary of state for international trade Elizabeth Truss last Thursday (February 6). The speech outlined plans for future trade agreements with non-EU countries during and after the Brexit transition period.
The BGMA welcomes sentiments in the manifesto to keep the NHS and the prices it pays for drugs “off the table” when seeking a trade deal with the US, he said.
However, Mr Smith warned that the UK’s “current intellectual property provisions”, which “balance the needs of the NHS and innovators”, must be maintained.
“The entry of one biosimilar medicine has saved the NHS £400 million in its first year so any delay would cost the NHS dear,” he added.